Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) Versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL

NCT04483739 is registered in ClinicalTrials.gov with European Myeloma Network B.V. as lead sponsor.

NCT NCT04483739
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04483739 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) Versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL
Lead sponsor
European Myeloma Network B.V.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 25, 2020
Completion date
December 31, 2032
Enrollment
302 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma